icon- folder.gif   Conference Reports for NATAP  
 
  XVII International AIDS Conference
Mexico City
3-8 August 2008
Back grey_arrow_rt.gif
 
 
 
Raltegravir 96 Weeks data from Phase II Study in Treatment-Naive
 
 
  Reported by Jules Levin
 
Police presence by my hotel
 

bil-1.gif

Sustained Antiretroviral Efficacy of Raltegravir as part of Combination ART in Treatment-Naive HIV-1 infected patients: 96-week data
 
M. Markowitz1, B.-Y. Nguyen2, E. Gotuzzo3, F. Mendo4, W. Ratanasuwan5, C. Kovacs6, H. Wan2, H. Campbell2, M. Miller2, R. Isaacs2, H. Teppler2, and the Protocol 004 Part II Study Team

www-2.gif

1Aaron Diamond AIDS Research Center, New York, NY; 2Merck Research Labs, West Point, PA; 3Hospital Nacionale Cayetano Heredia, Lima, Peru; 4Hospital Nacionale Edgardo Rebagliati, Lima, Peru; 6Maple Leaf Medical Center, Toronto, Canada; 5Siriraj Hospital, Bangkok, Thailand
 
AUTHOR CONCLUSIONS
 
At 96 weeks, RAL had sustained antiretroviral effect similar to 48 week data and to EFV (both with TDF/3TC)
 
--83% vs 84% (RAL vs EFV) with HIV RNA < 50 copies/mL
-- No new RAL mutations identified after 48 weeks
 
RAL was generally well tolerated at 96 weeks:
-- Drug-related AEs appeared less frequent for RAL vs. EFV
-- RAL had neutral effect on total cholesterol, LDL-C, and triglycerides.
SEE LIPIDS PROFILE BELOW

mk-3.gif

soory-4.gif

weeks-5.gif

mut-6.gif

sim-7.gif

effect-8.gif